|
Basic Characteristics of Mutations
|
|
Mutation Site
|
M184I |
|
Mutation Site Sentence
|
M184I was present in six monophyletic CRF01_AE isolates from untreated persons and was therefore not considered to be a subtype-specific polymorphism. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RT |
|
Standardized Encoding Gene
|
gag-pol:155348
|
|
Genotype/Subtype
|
HIV-1 CRF01_AE |
|
Viral Reference
|
M62320;K03455;U46016;M27323;AF005494;AF061642;AF005496;AF082394;AJ249235;U54771;L39106;AJ006022;L20587
|
|
Functional Impact and Mechanisms
|
|
Disease
|
HIV Infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
NRTIs |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
15839752
|
|
Title
|
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
|
|
Author
|
Kantor R,Katzenstein DA,Efron B,Carvalho AP,Wynhoven B,Cane P,Clarke J,Sirivichayakul S,Soares MA,Snoeck J,Pillay C,Rudich H,Rodrigues R,Holguin A,Ariyoshi K,Bouzas MB,Cahn P,Sugiura W,Soriano V,Brigido LF,Grossman Z,Morris L,Vandamme AM,Tanuri A,Phanuphak P,Weber JN,Pillay D,Harrigan PR,Camacho R,Schapiro JM,Shafer RW
|
|
Journal
|
PLoS medicine
|
|
Journal Info
|
2005 Apr;2(4):e112
|
|
Abstract
|
BACKGROUND: The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. METHODS AND FINDINGS: To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non-subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates. CONCLUSION: Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations.
|
|
Sequence Data
|
Dataset S1
|
|
|